[ TRANSACTION RECORD ]

AstraZeneca Investment in Icosavax — 2024

VERIFIED VECTOR ID: 001819 · tx-105
M SOURCE NODE — FUNDER
AstraZeneca
Healthcare United Kingdom
$1,100,000,000
EQUITY
19/02/2024
Q DESTINATION NODE — RECIPIENT
Icosavax
Company United States
Amount (USD)
$1.1B
Flow Type
EQUITY
Transaction Date
19/02/2024
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity AstraZeneca
AUM 230000
HQ Location United Kingdom
Sector Healthcare
Recipient Profile [ Q ]
Entity Icosavax
Entity Type Company
Jurisdiction United States
Intelligence Note

AstraZeneca completed the 1.1 billion dollar acquisition of Icosavax to strengthen its late-stage respiratory vaccine pipeline for older adults. The transaction includes a vaccine candidate for respiratory syncytial virus and human metapneumovirus. This deal underscores AstraZeneca’s commitment to expanding its vaccines and immune therapies division through strategic biotech takeovers.

Σ
Primary Forensic Source https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-icosavax-completed.html/
✓ SOURCE LINKED